Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: Brumar89 who wrote (1215894)	4/1/2020 7:34:08 PM
From: Broken_Clock	3 Recommendations Recommended By Taro TideGlider tntpal Read Replies (1) \| Respond to of 1578762

The deputy prime minister of Japan says that the WHO should be renamed the ‘Chinese Health Organization’ for its role in helping Beijing cover-up the severity of the coronavirus outbreak. Referring to a petition which now has almost 700,000 signatures calling on WHO Director-General Tedros Adhanom to resign, Taro Aso tore into the organization for conspiring with China and failing to stop a global pandemic that could have been prevented. “People think the World Health Organization should change its name. It shouldn’t be called the WHO, it should be renamed the Chinese Health Organization (CHO). This appeal is truly resonating with the people,” said Aso. “Early on, if the WHO had not insisted to the world that China had no pneumonia epidemic, then everybody would have taken precautions,” he added, noting that Taiwan had to face coronavirus on its own because it was excluded from the WHO.

To: Brumar89 who wrote (1215894)

4/1/2020 7:36:09 PM

From: Broken_Clock

Read Replies (2) | Respond to of 1578762

	of 434739

https://www.nytimes.com/2020/04/01/health/hydroxychloroquine-coronavirus-malaria.html Half the subjects — the controls — received just the usual care given to coronavirus patients, and half had usual care plus hydroxychloroquine. The usual care included oxygen, antiviral drugs, antibiotics and other treatments. Their disease was considered mild, even though all had pneumonia that showed up on CT scans. After giving informed consent, they were assigned at random to either the hydroxychloroquine or the control group. They were treated for five days, and their fevers and coughing were monitored. They also had chest CT scans the day before the study treatment began, and the day after it ended. Coughing and fever eased a day or so earlier in the patients who received hydroxychloroquine, and pneumonia improved in 25 of 31, as opposed to 17 of 31 in the controls. The illness turned severe in four patients — all in the control group. Two patients had minor side effects from hydroxychloroquine: One had a rash and another had a headache. Dr. Schaffner cautioned that the results applied only to patients with relatively mild illness, like the ones in the study, and could not be generalized to advanced cases. “If you want to treat people who are already seriously ill, we don’t know how well this will work,” he said.